Roche say cancer drug Alecensa gets breakthrough therapy designation
ZURICH (Reuters) - Roche said on Tuesday its lung cancer drug Alecensa (alectinib), developed by its Genentech unit, received a second breakthrough therapy designation (BTD) from the U.S. Food and Drug Administration (FDA) for its anaplastic lymphoma kinase (ALK) inhibitor.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Lung Cancer | Lymphoma